EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European Union to treat individuals with NSCLC.

O n Wednesday, China approved AstraZeneca plc's (NYSE:AZN) Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy for the 1st-line treatment of adult patients with ...

AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating its position as the ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

Tagrisso is also approved in combination with chemotherapy in the US, China and several other countries for 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC. Each year, ...

The data showed Tagrisso (osimertinib) slowed tumour progression compared with standard chemotherapy and was also more effective in patients with brain metastases – a group with a much worse ...

Johnson & Johnson JNJ announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving ...

TAGRISSO is approved for patients with EGFR mutations in the 1st-line metastatic setting as a monotherapy and in combination with chemotherapy, and as an adjuvant treatment for early-stage disease.

Tagrisso (osimertinib) is a brand-name oral tablet that’s prescribed for certain adults with non-small cell lung cancer (NSCLC). The cost of the drug with and without insurance can depend on ...

The global SAFFRON Phase III trial sponsored by AstraZeneca will further assess the TAGRISSO® plus ORPATHYS® combination versus platinum-based doublet chemotherapy in patients with EGFRm ...

Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...

Medscape Medical News, July 12, 2024 EU OKs First-Line Osimertinib+Chemo for EGFR+ Advanced NSCLC This decision is backed by results of the FLAURA2 trial, highlighting the efficacy of Tagrisso ...